Back to Main

Faculty Detail    
Campus Address WTI 510H Zip 3300
Phone  205-975-9878
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Hematology & Oncology Professor
Secondary  Biochemistry & Molecular Genetics  Biochemistry & Molecular Genetics Associate Professor
Secondary  Genetics   Genetics Chair Office Associate Professor
Center  Arthritis & Musculoskeletal Diseases Center  Arthritis & Musculoskeletal Diseases Center Professor
Center  Center for Biophysical Sciences/Engineering  Center for Biophysical Sciences/Engineering Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Professor
Center  General Clinical Research Center  Minority Health & Research Center Professor

Graduate Biomedical Sciences Affiliations
Biochemistry and Molecular Genetics Program 
Biochemistry and Structural Biology 
Cancer Biology 
Cellular and Molecular Biology Program 
Genetics, Genomics and Bioinformatics 
Integrative Biomedical Sciences 
Integrative Genetics Graduate Program 
Medical Scientist Training Program 
Pathobiology and Molecular Medicine 

Biographical Sketch 
Theresa Strong, Associate Professor of Medicine, received her B.S. in Biology from Cook College, Rutgers University in 1985. In 1989, she received a Ph.D. in Medical Genetics from the University of Alabama at Birmingham. She performed her postdoctoral work at the University of Michigan in the laboratory of Francis Collins, M.D., Ph.D. There, her studies focused on understanding the molecular basis of the inherited diseases cystic fibrosis and Huntington disease. She joined the UAB faculty in 1995.

Society Memberships
Organization Name Position Held Org Link
American Association for Cancer Research     
American Society of Gene Therapy     
American Society of Human Genetics     

Research/Clinical Interest
Identification of Tumor Antigens and Development of Cancer Vaccines
The major focus of our laboratory is the identification and characterization of novel tumor antigens, which may be useful in gene therapy of cancer. There is considerable evidence that the immune system can recognize tumor cells by virtue of tumor associated antigens, and a limited immune response to some of these antigens is detectable in patients. Gene therapy technology offers new strategies to stimulate the immune system to recognize tumor associated antigens and mount an effective antitumor immune response; however, current cancer immunotherapy approaches are limited by the lack of defined tumor antigens. The goal of our studies is to identify novel tumor associated antigens. Characterization of these antigens will provide insight into the origin and nature of human tumor antigens as well as into basic aspects of tumor biology. These antigens may also be useful for detection and diagnosis of cancer, and may provide novel targets for immunotherapy. Our group is also working on the development of vectors for gene delivery, with an emphasis on vectors for cancer immunotherapy. DNA-based vaccines for cancer immunotherapy have shown promise in model systems, but have had limited efficacy in the clinical setting. We are evaluating methods to modify the vectors and encoded antigens to produce more potent vaccines capable of breaking immunological tolerance. The goal of these studies is to develop cancer vaccines that may be useful to eliminate micrometastatic disease in patients at high risk for disease recurrence.

Selected Publications 
Publication PUBMEDID
Shaw DR, Strong TV. DNA Vaccines. Front Biosci 11:1189-98, 2006  16146806 
Aldrich WA, Ren C, White AF, Zho S-Z, Kumar S, Jenkins CB, Shaw DR, Strong TV, Triozzi PL, Ponnazhagan S. Enhanced transduction of mouse bone marrow derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 13:29-39, 2006.  16136165 
Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong, TV. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte macrophage colony stimulating hormone (GM-CSF). Vaccine 23:1273-1283, 2005  15652670 
Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, LoBuglio AF, Conry RM. Intratumoral administration of a recombinant canarypox virus expressing interleukin-12 in patients with metastatic melanoma. Human Gene Ther 16:91-100, 2005  15455351 
Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther. 15:856-64, 2004.  15353040 
Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer. 4:19, 2004.  15140265 
Straughn JM, Shaw DR, Guerrero A, Bhoola S, Racelis AS, Wang Z, Chiriva-Internati M, Grizzle WE, Alvarez RA, Lim S, Strong TV. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108:805-811, 2004.  14712480 
Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8:2782-2785, 2002  12231517 
Wang-Johanning F, Frost A, Johanning GL, Khazeali MB, LoBuglio AF, Shaw DR, Strong TV. Expression of human endogenous retrovirus K (HERV-K) envelope transcripts in human breast cancer. Clinical Can Res 7:1553-1560, 2001.  11410490 
Blackwell JL, Li H, Gomez-Navarro J, Krasnykh V, Shaw DR, Alvarez RA, Cuirel DT, Strong TV. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Human Gene Ther 11:1665-1677, 2000.  10954900 

tumor antigen, immunotherapy, vaccine